TY - JOUR
T1 - Valrubicin activates PKCa in keratinocytes
T2 - a conceivable mode of action in treating hyper-proliferative skin diseases
AU - Laugesen, Ina Groenkjaer
AU - Hauge, Eva
AU - Andersen, Stine Maria
AU - Stenderup, Karin
AU - de Darkó, Elisabeth
AU - Dam, Tomas Norman
AU - Rosada, Cecilia
PY - 2013/10
Y1 - 2013/10
N2 - Valrubicin is a semisynthetic anthracycline developed as an anti-cancer drug able to ameliorate psoriasis and non-melanoma skin cancer (NMSC) by topical application in animal models. Valrubicin decreases cell proliferation, and induces apoptosis; however its mode of action is still unknown. Valrubicin localizes in the cytoplasm and its valerate moiety resembles diacylglycerol, an activator of protein kinase C (PKC) α, which belongs to the PKC family of cytoplasmic serine/threonine protein kinases. PKCα is observed in the suprabasal layers of normal skin and is associated to keratinocyte growth arrest and differentiation processes. In hyper-proliferative skin diseases the presence of PKCα is altered.
AB - Valrubicin is a semisynthetic anthracycline developed as an anti-cancer drug able to ameliorate psoriasis and non-melanoma skin cancer (NMSC) by topical application in animal models. Valrubicin decreases cell proliferation, and induces apoptosis; however its mode of action is still unknown. Valrubicin localizes in the cytoplasm and its valerate moiety resembles diacylglycerol, an activator of protein kinase C (PKC) α, which belongs to the PKC family of cytoplasmic serine/threonine protein kinases. PKCα is observed in the suprabasal layers of normal skin and is associated to keratinocyte growth arrest and differentiation processes. In hyper-proliferative skin diseases the presence of PKCα is altered.
M3 - Journal article
C2 - 24085052
SN - 1545-9616
VL - 12
SP - 1156
EP - 1162
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 10
ER -